Sten Gunnar Otto Skolling
Director/Board Member at CHORDATE MEDICAL HOLDING AB
Network origin in Sten Gunnar Otto Skolling first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
18
| Public Company | Medical Specialties | 18 |
Karolinska Development AB (Private Equity)
 Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna.
13
| Operating Division | Investment Managers | 13 |
| Public Company | Pharmaceuticals: Major | 12 | |
| Public Company | Pharmaceuticals: Major | 9 | |
| Public Company | Miscellaneous Commercial Services | 9 | |
Athera Biotechnologies AB
 Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden.
8
| Holding Company | Pharmaceuticals: Major | 8 |
RespiNor AS
 RespiNor AS Electronic Equipment/InstrumentsElectronic Technology RespiNor AS operates as a medical device company. The company is headquartered in Oslo, Norway.
5
| Holding Company | Electronic Equipment/Instruments | 5 |
Umecrine AB
 Umecrine AB BiotechnologyHealth Technology Umecrine AB provides pharmaceuticals against mental and physical symptoms. It develops antagonists to reduce symptoms and conditions caused by endogenous sex and stress hormones on the brain. The company was founded by Carl Torbjörn Bäckström in 2000 and is headquartered in Umea, Sweden.
3
| Private Company | Biotechnology | 3 |
Biochromix AB
 Biochromix AB Medical SpecialtiesHealth Technology BioChromix AB manufactures diagnostic products. It is a company in the life science arena that develops and commercializes products for early stage diagnostics of Alzheimer's disease (AD) and identification of biomarkers associated to AD. The firm’s methods are based on their novel and patented Luminescent Conjugated Polymer (LCP) molecules. The company is headquartered in Solna, Sweden.
2
| Subsidiary | Medical Specialties | 2 |
Venture Cup Ost
2
| Private Company | 2 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Sten Gunnar Otto Skolling via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| NOVO NORDISK A/S | Pharmaceuticals: Major | Chairman Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| KARO PHARMA AB (PUBL) | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member Director/Board Member | |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal Director/Board Member Corporate Officer/Principal Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal | |
Industrifonden
 Industrifonden Investment ManagersFinance Industrifonden is a Venture Capital firm, a subsidiary of Government of Sweden founded in 1979. The firm is headquartered in Stockholm. | Investment Managers | Director of Investments Consultant / Advisor | |
| Karolinska Institutet | College/University | Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree Corporate Officer/Principal Doctorate Degree Corporate Officer/Principal Doctorate Degree | |
| OREXO AB | Pharmaceuticals: Major | Chief Executive Officer Director of Finance/CFO Corporate Officer/Principal | |
| Copenhagen Business School | College/University | Graduate Degree Masters Business Admin | |
| Chalmers University of Technology | College/University | Graduate Degree Graduate Degree Graduate Degree | |
| University of Uppsala | College/University | Masters Business Admin Undergraduate Degree Graduate Degree Graduate Degree Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree Graduate Degree Graduate Degree | |
Biolipox AB
 Biolipox AB Pharmaceuticals: MajorHealth Technology Biolipox AB develops and manufactures pharmaceuticals products. The company engages in the research and development of pharmaceuticals for the treatment of respiratory and other inflammatory diseases such as asthma, chronic obstructive pulmonary disease, rhinitis, pain, and arthritis. It was founded in June 2000 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal Director/Board Member | |
| INDEX PHARMACEUTICALS HOLDING AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chairman | |
Arexis AB
 Arexis AB Pharmaceuticals: MajorHealth Technology Arexis AB develops and manufactures pharmaceutical products. Its products are used for molecular dissection of metabolic and inflammatory diseases. The company was founded in 1999 and is headquartered in Goteborg, Sweden. | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal Founder | |
| University of Stockholm | College/University | Corporate Officer/Principal Graduate Degree Doctorate Degree Director/Board Member | |
| ONCOPEPTIDES AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member Corporate Officer/Principal | |
| Royal Institute of Technology | College/University | Graduate Degree Undergraduate Degree Graduate Degree Graduate Degree Doctorate Degree Graduate Degree | |
| University of Lund | College/University | Corporate Officer/Principal Corporate Officer/Principal Graduate Degree Doctorate Degree | |
| Umea Universitet | College/University | Doctorate Degree Corporate Officer/Principal Doctorate Degree | |
| University of Gothenburg | College/University | Corporate Officer/Principal Graduate Degree | |
KDev Exploratory AB
 KDev Exploratory AB Miscellaneous Commercial ServicesCommercial Services KDev Exploratory AB provides drug discovery solutions. It performs discovery research in various therapeutic areas, such as screening in oncology, neuroscience, lead finding, characterization in inflammation and angiogenesis/age-related macular degeneration. The company was founded by David Jern in 2000 and is headquartered in Solna, Sweden. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Chairman | |
Biosergen AS
 Biosergen AS BiotechnologyHealth Technology Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway. | Biotechnology | Chairman Chief Executive Officer Corporate Officer/Principal | |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Chief Executive Officer | |
Dilafor AB
 Dilafor AB Pharmaceuticals: MajorHealth Technology Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director of Finance/CFO Chairman Founder | |
| XSPRAY PHARMA AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| KCIF Fund Management AB | Director/Board Member Chief Executive Officer Chairman Chief Executive Officer | ||
Umecrine Cognition AB
 Umecrine Cognition AB Pharmaceuticals: MajorHealth Technology Umecrine Cognition AB develops pharmaceuticals against neurological disorders in the central nervous system. The firm focuses on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. The company was founded by Torbjörn Bäckström in 2006 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Founder | |
Akinion Pharmaceuticals AB
 Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Chief Executive Officer Director/Board Member Corporate Officer/Principal | |
| NEOS AB | Medical Specialties | Chairman Director/Board Member | |
AddBIO AB
 AddBIO AB BiotechnologyHealth Technology AddBIO AB provides bone implant technology solutions. It offers Zolidd, a bioactive nanolayer with a bone strengthening drug. The firm's Zolidd is used in the areas of dental and trauma implants. It also offers Zolidiser, a machine to add bone-strengthening drugs to implants. The company was founded by Per Aspenberg and Trine Vikinge in 2008 and is headquartered in Linköping, Sweden. | Biotechnology | Director/Board Member Chairman Director/Board Member | |
| KAROLINSKA DEVELOPMENT AB | Financial Conglomerates | Corporate Officer/Principal Chief Executive Officer Chairman Corporate Officer/Principal Director of Finance/CFO Chief Tech/Sci/R&D Officer Chief Executive Officer Chief Investment Officer Corporate Officer/Principal Director of Finance/CFO Corporate Officer/Principal Comptroller/Controller/Auditor | |
Palette Life Sciences AB
 Palette Life Sciences AB Medical SpecialtiesHealth Technology Palette Life Sciences AB operates as a pharmaceutical company. It specializes in developing products for local pain relief in obstetrics and gynecology. The company was founded by Berith Karlsson Tingåker, Gunvor Ekman-Ordeberg, Arne Folke Brodin and Lars Irestedt in 2009 and is headquartered in Solna, Sweden. | Medical Specialties | Chief Executive Officer Director/Board Member Director/Board Member Director/Board Member | |
KDev Oncology AB
 KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | Miscellaneous Commercial Services | Chief Executive Officer Director/Board Member Chairman Chief Executive Officer | |
| Arts Biologics A/S | Director/Board Member Chief Executive Officer | ||
Modus Therapeutics AB
 Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
KDev Investments AB
 KDev Investments AB BiotechnologyHealth Technology KDev Investments AB engages in research, sales, and development in the fields of medicine, biotechnology, pharmaceuticals, and medical technology. It also owns and manages investments of companies in the fields of medicine. Its portfolio will include both early and clinical stage pharmaceutical assets, as well as some technology assets. The company was founded on January 10, 2012 and is headquartered in Solna, Sweden. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
Betagenon Sweden AB
 Betagenon Sweden AB Pharmaceuticals: MajorHealth Technology Betagenon AB engages in development of AMP-activated protein kinase (AMPK) activator compounds chronic energy balance disorders diseases. The company was founded by Helena Edlund, Thomas Edlund and Olof Karlsson and is headquartered in Umea, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chairman | |
| SYNACT PHARMA AB | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
Arctic Asset Management AS (Sweden)
 Arctic Asset Management AS (Sweden) Investment ManagersFinance Arctic Asset Management AS (Sweden) (AAM-Sweden) is the Sweden-based investment management arm of Arctic Asset Management AS, ultimately owned by Arctic Securities AS in Norway. The firm was founded in 2016 and is headquartered in Stockholm. AFM-Sweden manages portfolio of Nordic equities, Nordic fixed income and Global Life Science – through mutual funds and discretionary mandates for institutional clients, family offices, investment companies and private clients. | Investment Managers | Founder Analyst-Equity | |
| LIPIGON PHARMACEUTICALS AB | Pharmaceuticals: Major | Chairman Director of Finance/CFO Director/Board Member |
Statistics
International
| Sweden | 43 |
| Denmark | 4 |
| United States | 3 |
| Iceland | 2 |
| Australia | 2 |
Sectoral
| Health Technology | 31 |
| Consumer Services | 10 |
| Commercial Services | 7 |
| Finance | 4 |
Operational
| Director/Board Member | 405 |
| Corporate Officer/Principal | 136 |
| Chairman | 127 |
| Chief Executive Officer | 79 |
| Independent Dir/Board Member | 69 |
Most connected contacts
| Insiders | |
|---|---|
| Göran Albert Ando | 44 |
| Bo Jesper Hansen | 34 |
| Stig Lennart Hansson | 32 |
| Carl Johan Kördel | 31 |
| Eva Nilsagård | 30 |
| Birgit Stattin Norinder | 29 |
| Torbjørn Bjerke | 27 |
| Urban Paulsson | 25 |
| Michael Owens | 25 |
| Mathieu Simon | 22 |
| Jan Nils Sandström | 20 |
| Peter Nordkild | 20 |
| Terje Kalland | 20 |
| Gunilla Lundmark | 20 |
| Carl Harald Janson | 19 |
- Stock Market
- Insiders
- Sten Gunnar Otto Skolling
- Company connections
